Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as hTERT
INO-1400 · 1 trial · 9 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | 2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 2 | EXPERIMENTAL | 8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 3 | EXPERIMENTAL | 2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 4 | EXPERIMENTAL | 2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 5 | EXPERIMENTAL | 8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 6 | EXPERIMENTAL | 8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 7 | EXPERIMENTAL | 2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 8 | EXPERIMENTAL | 8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 9 | EXPERIMENTAL | 8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Arm 10 | EXPERIMENTAL | 8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12 |
| Name | Type | Description |
|---|---|---|
| INO-1400 | BIOLOGICAL | - |
| INO-9012 | BIOLOGICAL | - |
| INO-1401 | BIOLOGICAL | - |
Inclusion Criteria: * 1\. Signed and dated written IRB approved informed consent; * 2\. Males or females aged ≥18 years; * 3\. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitiv...
Top 20 of 87 competitors
INO-1400 is an investigational monoclonal antibody developed by Inovio Pharmaceuticals, Inc. (ticker: INO). It is being studied in oncology, specifically in breast cancer, and targets the hTERT gene. INO-1400 has completed a Phase 1 clinical trial and is not approved for any indication.
INO-1400 is being developed for the treatment of breast cancer. It is an investigational therapy that has been studied in a Phase 1 clinical trial. It has not been approved by the FDA for breast cancer or any other indication, and further clinical development would be required before any potential use.
INO-1400 targets hTERT, the gene encoding human telomerase reverse transcriptase. By directing an immune response against hTERT, the therapy is designed to target cells expressing this gene. hTERT is a gene target, and INO-1400 is a monoclonal antibody being studied in breast cancer.
INO-1400 is being developed by Inovio Pharmaceuticals, Inc., which trades under the ticker INO. The company is the sponsor of the clinical program evaluating INO-1400 in oncology, including breast cancer.
INO-1400 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently in an active trial. INO-1400 is investigational and has not received FDA approval for breast cancer or any other indication.
INO-1400 has been evaluated in one completed Phase 1 trial, NCT02960594, titled hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse. The trial enrolled 93 participants across multiple solid tumor types, including breast cancer, and was conducted in the United States.